• Explore /
  • Poster
  • / Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.

Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.

Abstract Poster

Authors

null

Jason Alan Chesney

University of Louisville, Louisville, KY

Jason Alan Chesney , Igor Puzanov , Merrick I. Ross , Frances A. Collichio , Mohammed M. Milhem , Lisa Chen , Jenny J. Kim , Claus Garbe , Axel Hauschild , Robert Hans Ingemar Andtbacka

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT01740297

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9509)

DOI

10.1200/JCO.2017.35.15_suppl.9509

Abstract #

9509

Poster Bd #

117

Abstract Disclosures

Similar Posters

First Author: Suzanne Phillips

First Author: Wei Wei

First Author: Giorgio V. Scagliotti

First Author: Maria Constantinou